Global Non-Small Cell Lung Cancer Diagnostics Market Booming Worldwide To Show Significant Growth By 2028||QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV

Data Bridge Market research presents the top quality and comprehensive Non-Small Cell Lung Cancer Diagnostics research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This Non-Small Cell Lung Cancer Diagnostics report deeply study competitive scenario and evaluated the crucial vendors with regard to product stratification and business strategies. It analyzes the detailed insight with respect to industries and geographies. The detailed information of the existed industries is the first acquired by the dedicated team to provide exact and accurate data of the market.

The global non-small cell lung cancer diagnostics market is expected to reach USD 3,463.37 million by 2028 from USD 1,291.66 million in 2020, growing at a steady CAGR of 13.2% in the forecast period of 2021 to 2028.

Get Sample Copy Of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-non-small-cell-lung-cancer-diagnostics-market&kb

Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co., Ltd, Oncimmune, Biodesix. among others.

The global non-small cell lung cancer diagnostics market is fragmented, and the major players have used various strategies such as collaborations, recognitions, agreements, and others, to increase their footprints in the non-small cell lung cancer diagnostics market.

For instance,

In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions.
In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
In June 2020, F. Hoffmann-La Roche Ltd launched an automated digital pathology algorithm, uPath PD-L1 (SP263) image analysis , to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment

Points Which Are Focused In the Report

Industry Chain Suppliers of Xyz market with Contact Information
The key findings and recommendations highlight crucial progressive industry trends in the Non-small cell lung cancer diagnostics Market, thereby allowing players to develop effective long term strategies
To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the Non-small cell lung cancer diagnostics market
To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders
To understand the future outlook and prospects for Non-small cell lung cancer diagnostics market analysis and forecast 2021-2028.

Scope of the Non-small cell lung cancer diagnostics Market

Global non-small cell lung cancer diagnostics market is segmented on the basis of countries into the U.S., Mexico, Canada, France, Russia, Netherlands, U.K., Germany, Italy, Spain, Turkey, Belgium, Switzerland, and the rest of Europe, China, Thailand, Australia, Japan, South Korea, Singapore, Malaysia, Indonesia, Philippines, India, and rest of Asia-Pacific, South Africa, Egypt, Saudi Arabia, UAE, Israel and rest of the Middle East and Africa, Brazil, Argentina and Rest of South America.

All country-based analysis of the global non-small cell lung cancer diagnostics market is further analyzed based on maximum granularity into further segmentation. On the basis of cancer type, the global non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell carcinoma, and others. On the basis of products, the global non-small cell lung cancer diagnostics market is segmented into reagents and kits, instruments and services, and software. On the basis of tests, the global non-small cell lung cancer diagnostics market is a segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry, and others. On the basis of end-user, the global non-small cell lung cancer diagnostics market is segmented into hospitals, clinical laboratories, academies and institutes, and research centers.

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-non-small-cell-lung-cancer-diagnostics-market&kb

North America Non-Small Cell Lung Cancer Diagnostics Market Scenario

According to Data Bridge Market Research, the market for North America non-small cell lung cancer diagnostics in North America has the highest market share. Market leader is Abbott, which accounts an estimated market share of approximately 22.00% in the North America market. The company has gained outstanding sale by launching products of non-small cell lung cancer diagnostics.

In October 2020, Abbott expanded its business by launching companion diagnostics, Vysis ALK Break Apart FISH Probe Kit in Europe, to diagnose non-small cell lung cancer patients eligible for XALKORI treatment

Non-Small Cell Lung Cancer Diagnostics Market Developments

In June 2020, F. Hoffmann-La Roche Ltd launched automated digitalpathology algorithm, uPath PD-L1 (SP263) image analysis to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment. This new launch of the algorithm helped the pathologiest to assess the disease more effectively.
In June 2021, Quest Diagnostics Incorporated partnered with Biocept to offer its target selector next-generation sequencing (NGS)-based liquid biopsy targeted lung cancer panel to the customers and also use Biocept’s less invasive, lab-developed assay to conduct genomic profiling in advanced NSCLC patients. This partnership helped the company offer their product to a large consumer base and develop more advanced technology.

Key Pointers Covered in Non-Small Cell Lung Cancer Diagnostics Market Industry Trends and Forecast to 2028

Market Size
Top to Bottom Market Analysis
Recent Developments for Market Competitors
Recent Market Value for Different Countries
Market value and over view of Non-small cell lung cancer diagnostics market
Company profiling of top eight players of Non-small cell lung cancer diagnostics market

Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-non-small-cell-lung-cancer-diagnostics-market&kb

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.